“Just breathing can be such a luxury at times.”
The Breakthrough in Non-Inflatable Supraglottic Airway Management
Home to the intellectual property and clinical biomechanics developed by renowned consultant anesthesiologist Dr. Muhammed Aslam Nasir (Macewen Medal Recipient). Powering i-gel® in human emergency medicine and v-gel® in species-specific veterinary anaesthesia across 100+ countries.
Zero inflatable cuff. Zero mucosal capillary ischemia. Licensed globally to Intersurgical Ltd.
Countries Deployed
Routine & emergency careProcedures Worldwide
Human & veterinary patientsCuff Inflation Trauma
Pressure-neutral soft gel sealMacewen Medal
Awarded to Dr. M.A. Nasir (DAS)Where Dr. Nasir's Airway Inventions Protect Lives
Inflatable Balloon Cuff vs. Non-Inflatable Anatomical Gel Seal
Dr. Muhammed Aslam Nasir recognized that conventional airway cuffs create hydrostatic pressures far exceeding mucosal capillary perfusion pressure, causing ischemic tissue trauma.
Balloon Compression and Distension
Standard supraglottic airways rely on air inflation through a pilot balloon. In clinical practice, overinflation occurs in over 80% of routine cases, creating pressures reaching 80–120 cmH2O.
Pressure-Neutral Anatomic Gel Seal
Dr. Nasir eliminated the cuff entirely. Engineered from medical-grade SEBS thermoplastic elastomer, the seal mirrors human and veterinary anatomy, generating an airtight seal without mechanical tissue stress.
Engineered for Human Critical Care & Veterinary Precision
Two revolutionary applications of Dr. Nasir’s patented supraglottic technology, each customized for anatomical physiology.
i-gel® Supraglottic Airway
Human Anaesthesia & ResuscitationThe 2nd Generation Supraglottic Airway with Non-Inflatable Perilaryngeal Anatomy Seal
The gold-standard non-inflatable supraglottic airway device used in routine anaesthesia, difficult airway algorithms, and emergency resuscitation worldwide.
v-gel® & v-gel® Advanced Veterinary Airway
Species-Specific Veterinary AnaesthesiaThe World’s First Species-Specific Supraglottic Airway Devices for Veterinary Medicine
Species-specific anatomically contoured supraglottic airway device preventing tracheal trauma and delivering safe positive-pressure ventilation in veterinary anaesthesia.
i-gel® Anatomical Architecture & Seal Biomechanics
Click on any numbered anatomical marker or feature tag to inspect its engineering and clinical significance.
Non-Inflatable Anatomical Gel Seal
Medical-grade SEBS | Pressure-neutral contact (<20 cmH2O) | Oropharyngeal seal >30 cmH2O
The core breakthrough invented by Dr. Muhammed Aslam Nasir: molded from soft medical-grade thermoplastic elastomer (SEBS) accurately mirroring perilaryngeal anatomy without air inflation.
Creates an airtight seal (>30 cmH2O) matching aryepiglottic folds, pyriform fossae, and thyroid cartilage with zero cuff pressure, eliminating mucosal ischemia, nerve damage, and post-op sore throat.
Interactive Airway Selector
Determine anatomical sizing, suction tube Fr, and airway parameters based on patient weight.
i-gel® Medium Adult (Gold Standard)Size 4
The Visionaries Behind TALRIA LIMITED DMCC
A cohesive leadership team combining world-class clinical invention, precision biomedical engineering, multinational licensing, and corporate governance.
Dr. Muhammed Aslam Nasir
"Just breathing can be such a luxury at times. Our purpose was simple yet profound: design an airway that mirrors human and animal anatomy so naturally that inflation, pressure trauma, and tissue ischemia become obsolete."
Dr. Muhammed Aslam Nasir is a world-renowned consultant anaesthesiologist, medical innovator, and the pioneering inventor behind the i-gel® human supraglottic airway device and the v-gel® species-specific veterinary airway system. With decades of frontline clinical experience in anaesthesia and critical care, Dr. Nasir revolutionized supraglottic airway management by discovering that an anatomically molded thermoplastic elastomer could replace traumatic inflatable balloons. In 2016, Dr. Nasir was awarded the prestigious Macewen Medal by the Difficult Airway Society (DAS, UK) for outstanding and lasting contribution to airway management. He also serves as President of Docsinnovent Ltd and is the founder of Light4Life, a philanthropic foundation providing emergency disaster relief and education.
Dr. Muhammed Aslam Nasir
President, Docsinnovent Ltd
MD, TALRIA LIMITED DMCC
Bestowed by the Difficult Airway Society (DAS) for transformative contributions to airway safety.
DirectorTalha Nasir
COO
Talha Nasir serves as Chief Operating Officer (COO) across TALRIA LIMITED DMCC’s medical and veterinary portfolios. With a scientific foundation in marine biology and environmental sciences, he directs operational execution, regulatory compliance, quality management, and sustainable biomedical development. Working closely with international manufacturing partners and clinical research teams, he oversees operational strategy to ensure every generation of supraglottic device complies strictly with international directives (MDR 2017/745, ISO 13485, and US FDA requirements), uniting rigorous biological insight with high-precision global operations.
DirectorMr. Tuaha Nasir
Director of Business Development
Mr. Tuaha Nasir spearheads international business development, strategic licensing alliances, and commercial channel expansion for TALRIA LIMITED DMCC. Managing corporate relationships with multinational medical device distributors, contract manufacturing partners, and clinical purchasing syndicates, Tuaha has been instrumental in scaling the commercial footprint of Dr. Nasir’s airway technologies across Europe, North America, the Middle East, and Asia. He also directs cross-border trade operations and serves as a director in family commercial enterprises and charitable initiatives including Light4Life.
DirectorMr. Adam Nasir
Director of Business Development
Mr. Adam Nasir leads market penetration strategies, clinical education initiatives, and veterinary institutional integration for TALRIA LIMITED DMCC. He focuses on building long-term alliances with veterinary teaching hospitals, university anaesthesia departments, private veterinary clinic groups, and military medical academies. Adam’s market-building expertise drives rapid clinical adoption by demonstrating how the transition from cuffed endotracheal tubes to non-inflatable supraglottic airways dramatically lowers patient morbidity and accelerates surgical turnover.
DirectorMr. Danyal Nasir
Financial Director
Mr. Danyal Nasir directs corporate finance, treasury operations, IP valuation, and fiscal governance for TALRIA LIMITED DMCC. Overseeing the enterprise’s financial architecture from the Dubai Multi Commodities Centre (DMCC) headquarters, Danyal coordinates cross-border royalty streams, investment allocation for clinical trials, tax-efficient IP asset stewardship, and compliance with UAE Free Zone and international statutory accounting standards. His stewardship provides the fiscal backbone that fuels continuous R&D and global patent protection.
General ManagerMr. Touseef Akhtar
General Manager
Mr. Touseef Akhtar directs strategic operations, commercial development, and R&D pipelines for TALRIA LIMITED DMCC from the company's headquarters in the Dubai Multi Commodities Centre (DMCC). Bringing extensive multi-sector experience in Pharma, healthcare and medical device innovation, Mr. Akhtar leads the enterprise's research initiatives, product engineering roadmaps, and global clinical validation strategies. Working in alignment with the firm's fiscal and corporate governance framework—overseen by Company Directors —Mr. Akhtar coordinates cross-border technology transfers, regulatory compliance protocols, and commercialization pathways for advanced medical technologies. His leadership bridges scientific innovation with rigorous operational execution, driving the continuous development and global market introduction of proprietary medical devices.
Global Adoption Across 100+ Healthcare Jurisdictions
From premier university operating theatres to frontline paramedic response in extreme environments.
TALRIA LIMITED DMCC (Global Corporate Seat)
Dubai Multi Commodities Centre, Dubai, UAE
Backed by Multi-Center Trials & Resuscitation Protocols
Effect of a Strategy of a Supraglottic Airway Device vs Tracheal Intubation During Out-of-Hospital Cardiac Arrest (AIRWAYS-2 Trial)
A landmark multicenter cluster-randomized clinical trial involving 9,296 adult patients with non-traumatic out-of-hospital cardiac arrest attended by 1,523 paramedics from four ambulance services in England.
Demonstrated high initial airway placement success rates for i-gel® (87.4% on first attempt), confirming its reliability as a frontline resuscitation airway in emergency medical systems.
Difficult Airway Society 2015 Guidelines for Management of Unanticipated Difficult Intubation in Adults
The definitive guidelines for unanticipated difficult intubation in general anaesthesia. Specifies 2nd generation supraglottic airway devices with gastric channels as Plan B rescue devices.
Recommends second-generation supraglottic airways such as i-gel® for rescue oxygenation due to superior seal pressures and esophageal vent protection against aspiration.
Size 4 i-gel Airway Insertion During Chest Compressions in a Manikin Simulation
Investigated the feasibility and speed of inserting an i-gel airway during continuous uninterrupted external cardiac compressions.
100% of insertions succeeded without interrupting CPR chest compressions, with median insertion times under 8 seconds.
Initiate Clinical or Commercial Partnership
Connect directly with TALRIA LIMITED DMCC leadership regarding global IP licensing, veterinary clinical distribution, hospital group procurement, or academic research collaborations.